The Latin America, Middle East and Africa Hemophilia Market would witness market growth of 12.1% CAGR during the forecast period (2023-2030).
The introduction of technologically sophisticated diagnostic tools and therapies to improve the efficacy and accuracy of hemophilia therapy is another focus of top industry players. Early diagnosis and better treatment of hemophilia have been made possible by increased knowledge of the disorder among patients and healthcare providers. As a result, more patients are being discovered and obtaining the proper care, which supports market expansion. Intravenous infusions are the main form of treatment, which involve adding extra clotting factor to the patient's blood. With bleeding diseases, surgeries are performed with extra caution. As a result, the patient's surgeon needs to be aware of this problem. It is also crucial to educate blood relatives about the issue because they can possibly develop the condition.
Due to greater awareness, improved healthcare infrastructure, and higher disposable incomes, the hemophilia market is expanding in emerging countries. Hemophilia medicines are increasingly being used in emerging economies, which is further fueling market expansion. Patient organizations and advocacy groups for hemophilia are essential in educating the public, assisting patients, and influencing healthcare regulations. Their efforts enhance people's access to resources and therapies, which has a favorable effect on the market.
Large families, advanced maternal and paternal ages, and consanguinity rates—the number of marriages between close relatives—commonly found in the Middle East and Africa region all play a key role in the higher occurrence of genetic and congenital disorders. In Saudi Arabia, congenital malformations account for a sizable part of perinatal deaths, and they rank second among the causes of infant mortality in Bahrain, Kuwait, Oman, and Qatar. Additionally, because of the burgeoning pharmaceutical industry in this region, there is a rising need for contemporary treatments. Because it is anticipated that regional pharmaceutical industry sales will rise over the coming few years, there is a significant probability that an investment will pay off. The need for hemophilia therapies will grow dramatically in this region during the next few years, driving the expansion of the market.
The Brazil market dominated the LAMEA Hemophilia Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $352.9 million by 2030. The Argentina market is showcasing a CAGR of 12.7% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 11.8% during (2023 - 2030).
Based on Distribution Channel, the market is segmented into Specialty Pharmacies, and Hospital Pharmacies. Based on Type, the market is segmented into Hemophilia A, Hemophilia B, and Others. Based on Treatment Type, the market is segmented into Prophylaxis, On-demand, and Cure. Based on Therapy, the market is segmented into Factor Replacement Therapy (Recombinant Factor Concentrates, and Plasma-derived Factor Concentrates), Desmopressin & Fibrin Sealants, and Gene Therapy & Monoclonal Antibodies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Hemophilia Market is Projected to reach USD 18.3 Billion by 2030, at a CAGR of 6.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, CSL Limited (CSL Behring), Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB (Investor AB) and Sanofi S.A.
By Distribution Channel
By Type
By Treatment Type
By Therapy
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
